Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patritumab - Amgen/Daiichi Sankyo

Next Previous
X
Search
Drug Profile

Patritumab - Amgen/Daiichi Sankyo

Alternative Names: AMG-888; U3-1287

Latest Information Update: 30 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; U3 Pharma
  • Developer Daiichi Sankyo Company; U3 Pharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 30 Jul 2024 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (IV)
  • 30 Jul 2024 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 30 Jul 2024 Discontinued - Phase-II for Head and neck cancer (Combination therapy, First-line therapy, Metastatic disease) in Belgium (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top